PROVIDENCE – Rubius Therapeutics Inc. has appointed Natalie Holles to its board of directors and Greg Whitehead as senior vice president and chief quality officer.
Rubius, based in Cambridge, Mass., but with a facility under renovation in Smithfield, is a clinical-stage biopharmaceutical company generating red blood cells and bioengineering them into a new class of cellular medicines.
Cross Insurance Expands Rhode Island Presence with New Providence Office
Cross Insurance is strengthening its presence in Rhode Island with its new Providence office, a…
Learn More
Dr. Roger Pomerantz, who has served as a board member since Rubius’ founding, has decided not to stand for reelection, with his board membership ending by June 2019.
“It takes great people to build a great company, and I could not be more thrilled to welcome Natalie and Greg to the Rubius team,” said Dr. Pablo J. Cagnoni, president and CEO of Rubius. “With Rubius on the cusp of treating the first phenylketonuria patients with RTX-134, Natalie’s extensive background in company-building, corporate development, strategic planning and commercial readiness, along with Greg’s expertise in leading quality teams from early manufacturing processes to regulatory interactions and global commercialization will be invaluable to us as we enter the clinic and plan for the future.”
Currently serving as the president and CEO of Audentes Therapeutics Inc., Holles has more than 20 years of experience in corporate development, strategic planning and operations leadership, with a focus on orphan diseases.
Whitehead brings more than 25 years of quality-related experience to Rubius, the company said. He joins Rubius from bluebird bio Inc., where he most recently served as vice president of quality.
“On behalf of Rubius, I would like to thank Roger for his many contributions toward our success since the company’s founding,” Cagnoni said. “His strategic counsel has helped advance our company to where we are today.”
Rob Borkowski is a PBN contributing writer.
